FX-322

N/A

Report date: 2022/11/14 13:45:24
NME

Base Information

Drug NameFX-322
Drug Alias NameFZ-322FX-322
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHistone deacetylase inhibitorsGlycogen synthase kinase-3 inhibitorsWnt signalling pathway stimulants
TargetsHistone deacetylaseGlycogen synthase kinase-3
Therapy Area/IndicationsHearing Loss, SuddenPresbycusisHearing Loss, Noise-Induced +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia
CombinationsYes
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesFrequency Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesFrequency TherapeuticsAstellas Pharma Inc
Inactive CompaniesN/A
Active IndicationsHearing Loss, SuddenPresbycusisHearing Loss, Noise-Induced +[4] 
Inactive IndicationsHearing Loss

Other Information

ATC CodeN/A
Related LinksN/A